Shares of Stryker SYK decreased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 12.85% over the past year to $2.81, which beat the estimate of $2.55.
Revenue of $4,262,000,000 rose by 3.17% from the same period last year, which missed the estimate of $4,330,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Jan 27, 2021
Time: 04:00 PM
Price Action
Company's 52-week high was at $247.44
Company's 52-week low was at $124.54
Price action over last quarter: Up 14.23%
Company Profile
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Slightly more than a quarter of Stryker's total revenue currently comes from outside the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
